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Thyroid cancer incidence is rapidly increasing due to increased detection and diagnosis of indolent thyroid cancer,
i.e. cancer that is likely to be clinically insignificant. Clinical, radiologic, and pathologic features predicting indolent
behavior of thyroid cancer are still largely unknown and unstudied. Existing clinicopathologic staging systems are
useful for providing prognosis in the context of treated thyroid cancer but are not designed for and are inadequate
for predicting indolent behavior. Ultrasound studies have primarily focused on discrimination between malignant
and benign nodules; some studies show promising data on using sonographic features for predicting indolence
but are still in their early stages. Similarly, molecular studies are being developed to better characterize thyroid
cancer and improve the yield of fine needle aspiration biopsy, but definite markers of indolent thyroid cancer have
yet to be identified. Nonetheless, active surveillance has been introduced as an alternative to surgery in the case of
indolent thyroid microcarcinoma, and protocols for safe surveillance are in development. As increased detection of
thyroid cancer is all but inevitable, increased research on predicting indolent behavior is needed to avoid an
epidemic of overtreatment.
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Thyroid cancer incidence in the United States has more
than tripled since 1973 [1–4]. Analysis of the National
Cancer Institute’s (NCI) Surveillance, Epidemiology, and
End Results (SEER) database over the period 1975–2009
by Davies and Welch suggests that virtually the entirety of
the increase is due to greater detection and diagnosis of
papillary thyroid carcinoma [2]. In principle, increased
detection and treatment of early cancers is of benefit when
associated with a decrease in cancer-related mortality; in
reality, thyroid cancer-related mortality has not appre-
ciably changed for at least 30 years because the vast ma-
jority of these cancers are indolent. The result instead has
been increased surgery and procedure-related morbidity
without a proven benefit in patient outcomes. By some
estimates, the medical costs of thyroid cancer exceed 1.6
billion dollars a year in the U.S. [4, 5], and this figure is
projected to more than double by 2030.* Correspondence: tsdesser@stanford.edu
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(http://creativecommons.org/publicdomain/zeAlthough thyroid nodules are palpable in only 4–7% of
adults [6, 7], the prevalence of thyroid nodules visible on
ultrasound may be up to 67% [8]. Assuming an approxi-
mate 10% chance of any given thyroid nodule being
malignant, this implies that millions of Americans have
clinically occult thyroid cancer that is merely one ultra-
sound scan away from detection. Therefore, it has become
crucial to not only identify thyroid cancer, but to also dis-
tinguish those thyroid cancers destined for indolent behav-
ior from those likely to behave aggressively.
The goal of this review is to clarify what is known about
identifying thyroid cancers that are likely to be clinically
insignificant, and what questions still need to be investi-
gated. We discuss the properties of indolent thyroid can-
cer as identified by clinical data, sonographic features,
histopathology, and molecular markers in relation to the
current guidelines and principles used to evaluate thyroid
cancer. In addition, we discuss the management of indo-
lent thyroid cancer.Clinicopathologic prognostic factors
Current guidelines for determining thyroid cancer prog-
nosis are based on a variety of staging systems that classifyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 TNM staging for differentiated cancers (papillary
and follicular)
Primary Tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor 2 cm or less in greatest dimension limited
to the thyroid
T1a Tumor 1 cm or less, limited to the thyroid
T1b Tumor more than 1 cm but not more than 2 cm
in greatest dimension, limited to the thyroid
T2 Tumor more than 2 cm but not more than 4 cm
in greatest dimension limited to the thyroid
T3 Tumor more than 4 cm in greatest dimension
limited to the thyroid or any tumor with minimal
extrathyroid extension (e.g., extension to sternothyroid
muscle or perithyroid soft tissues)
T4a Moderately advanced disease: Tumor of any size
extending beyond the thyroid capsule to invade
subcutaneous soft tissues, larynx, trachea, esophagus,
or recurrent laryngeal nerve
T4b Very advanced disease
Tumor invades prevertebral fascia or encases carotid
artery or mediastinal vessels
Regional Lymph Nodes (N) Regional lymph nodes are the central compartment,
lateral cervical, and upper mediastinal lymph nodes.
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
N1a Metastasis to Level VI (pretracheal, paratracheal, and
prelaryngeal/Delphian lymph nodes)
N1b Metastasis to unilateral, bilateral, or contralateral cervical
(Levels I, II, III, IV, or V) or retropharyngeal or superior
mediastinal lymph nodes (Level VII)
Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Age less than 45 years
Stage I Any T Any N M0
Stage II Any T Any N M1
Age greater than 45 years
Stage I T1 N0 M0
Stage II T2 N0 M0










Stage IVB T4b Any N M0
Stage IVC Any T Any N M1
Used with permission of the American Joint Committee on Cancer (AJCC),
Chicago, Illinois. The original and primary source for this information is the
AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer
Science + Business Media
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The primary features of TNM staging are size of tumor/
extrathyroidal spread, extent of spread to lymph nodes,
and the presence of distant metastases (Table 1). Large
size of tumor, extrathyroidal extension, and the presence
of distant metastases have separately shown consistent
correlation with cancer-specific mortality [9–11]. Many
(though not all) studies also support the association of
nodal spread at presentation with mortality [10, 11].
Unlike other cancers, thyroid TNM staging also incorpo-
rates patient age, as advanced age confers poor prognosis
for both mortality and recurrence [12]. Current TNM
staging as proposed by the American Joint Committee on
Cancer (AJCC) and Union for International Cancer
Control (UICC) upstages some cancers in patients greater
than 45 years of age. Recently, the hard cutoff of 45 has
been challenged as mortality continues to increase with
age, and the use of a nomogram to determine stage based
on age as a continuous variable may yield improved
prediction of prognosis [12]. Similar criticism could con-
ceivably be directed at other variables of the TNM system.
Nonetheless, TNM staging remains a well-validated tool
for initially stratifying patients into four categories differ-
ing by cancer-specific mortality [9, 13]. Another com-
monly used system is the MACIS system developed at the
Mayo clinic (Table 2) which calculates a score based on a
similar set of features that also reliably stratifies patients
into four prognostic categories [13]. One recent Danish
prospective study followed a cohort of 1350 patients with
papillary thyroid carcinoma over a median time of
7.9 years to assess the accuracy of the 5th edition of
TNM, MACIS, and additional staging systems. [13] TNM
staging and MACIS both achieved high statistical signifi-
cance in distinguishing stages by cancer specific mortality,
thus validating their use in a modern cohort.
TNM staging is limited in its prediction of disease
recurrence, and therefore the American Thyroid Association
(ATA) provides a separate Initial Risk Stratification System
to divide patients with well differentiated thyroid cancer into
three risk groups differing by likelihood of recurrence. In
addition to incorporating TNM features, these guidelines
also incorporate some factors related to initial treatment.
High-risk features include incomplete tumor resection or
postoperative serum thyroglobulin levels suggestive of
distant metastases. Intermediate-risk features include RAI-
avid metastatic foci of the neck on post-treatment whole-
body RAI scan, clinical N1, microscopic perithyroidal
invasion and others. Low risk features include papillary can-
cers with no local or vascular invasion, no local or distant
metastases, and complete macroscopic tumor resection. Ini-
tial Risk Stratification System also takes into account histo-
pathology, and defines patients with aggressive histologies
such as tall cell, insular, or columnar cell variants, or vascu-
lar invasion, as being at higher risk of recurrence [14, 15].Despite their widespread use, TNM staging for mortality
and ATA risk stratification for recurrence demonstrate
relatively low proportion of variance explained (PVE), a
statistical measure that can be used to assess prognosis
classification systems. This likely relates to an extremely
Table 2 MACIS scoring and staging
MACIS Score components
Metastases 3 if distant spread
Age 3.1 (if age <40 years) or 0.08 × age (if
age≥ 40 year)
Completeness of Resection 1 if incompletely resected, 0 otherwise
Invasion (local) 1 if locally invasive, 0 otherwise
Size 0.3 × tumor size (cm maximum diameter)





Fig. 1 High suspicion pattern. Transverse grayscale sonographic image
of the thyroid at level of isthmus shows a hypoechoic, irregularly
marginated thyroid nodule containing microcalcifications (arrow). This is
a “high suspicion” sonographic pattern in the 2015 ATA guidelines, with
an estimated risk of malignancy of >70–90%. Fine-needle aspiration of
this nodule showed papillary thyroid carcinoma
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ies have proposed and validated dynamic systems of risk
stratification, in which patients are reassessed following
each round of treatment using a combination of imaging
findings and thyroglobulin, which dramatically increased
PVE for recurrence from 25–34% to 62–84 [16, 17]. It is
important to recognize, however, that risk stratification
would ideally be performed before any major intervention,
and that prediction of indolent behavior in the absence of
treatment is a distinct goal from determining prognosis
after treatment. Any thyroid cancer with evidence of
regional or distant spread could not be considered indo-
lent and would certainly require intervention (though this
may require further evaluation in the future). However,
SEER data from 1973 to 2013 indicate that 68% of thyroid
cancers are confined to the thyroid at diagnosis [18], and
other studies show that an even higher percentage may be
associated with micrometastases that are not clinically
significant (14). The task, then, is to identify which of these
majority of well-differentiated thyroid cancers are indolent.
Small tumor size in itself is a good first clue, as the
vast majority of thyroid microcarcinoma, defined as thy-
roid cancer less than one centimeter in size, is indolent.
This is well demonstrated by autopsy studies which
found a prevalence of thyroid microcarcinoma 10–100
times greater than the prevalence of microcarcinoma
which presents clinically [19]. In keeping with the hypoth-
esis that increased thyroid cancer detection is responsible
for increased thyroid incidence, microcarcinomas now
account for a bulk of newly detected thyroid cancer.
Microcarcinomas represented 39% of all cancers identified
in the United States from 2008 to 2009, versus 25% in
1988–89 [2]. The relative proportion of cancers larger
than 2 cm decreased from 42 to 33% over the same
period. In an effort to stave off a diagnostically induced
epidemic of thyroid microcarcinoma, current guidelines
by the ATA [14] and Society of Radiologists in Ultrasound
(SRU) [20] recommend abstaining from fine needleaspiration of thyroid nodules less than a centimeter in
size; a small thyroid nodule may be considered benign or
indolent until proven otherwise. Appropriate follow-up is
then determined on the basis of the presence or absence
of worrisome sonographic features within the thyroid
nodule and the surrounding neck.
Sonographic prognostic factors
Ultrasound would be an ideal tool for prediction of
indolent cancer, given that diagnosis of thyroid cancer
almost always begins with sonographic evaluation of a
thyroid nodule. An array of sonographic features has
been used to describe thyroid nodules and identify those
with features suspicious for malignancy. These features
include microcalcifications, irregular borders, increased
vascularity, taller-than-wide morphology, and marked
hypoechogenicity (Fig. 1) [21, 22], though no single fea-
ture individually has proved to be very sensitive or spe-
cific. Conversely, a few sonographic patterns have been
reliably associated with benignity in thyroid nodules,
including a “spongiform” appearance (Fig. 2), an echo-
genic appearance in the setting of Hashimoto’s thyroid-
itis termed a “white knight” nodule (Fig. 3), a “giraffe
skin” appearance, and a purely cystic nodule containing
colloid without flow [23–25]. Elastography, a relatively
new sonographic technique which assesses nodule stiff-
ness, appears to correlate with malignancy, but further
validation and wide-spread adoption will be required
before stiffness measurements can be incorporated into
routine thyroid nodule evaluation [26].
Recent efforts have been made to standardize report-
ing of thyroid nodule findings and help stratify risk of
malignancy [22], some of which have been described as
a Thyroid Imaging Reporting and Data System [27, 28]
(TI-RADS) analogous to BI-RADS for cataloguing breast
Fig. 2 Very low suspicion pattern. Transverse grayscale sonographic
image of the thyroid at level of thyroid isthmus shows a nodule in the
right lobe (arrow) with a “spongiform” pattern. Note the innumerable
tiny cystic spaces characteristic of this pattern
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the process of developing its own TI-RADS system and
has proposed a lexicon for describing thyroid nodules
[29]. The ATA makes specific recommendations for
biopsy based on different risk categories of sonographic
features paired with lesion size (Table 3). While these ef-
forts are important steps toward standardization and de-
termining management according to current guidelines,
to date most work has involved the binary classification of
nodules as benign or suspicious for malignancy. Future
research must add nuance to this characterization ques-
tion and aim to identify which sonographic features of
nodules predict not just malignancy, but an aggressive thy-
roid cancer versus an indolent thyroid cancer versus a
benign thyroid nodule.
A small number of studies have begun to investigate
sonographic prediction of aggressive tumor behavior.
Most assess the association of findings on pre-operative
ultrasound with extracapsular extension and lymph nodeFig. 3 Very low suspicion pattern. Transverse and longitudinal sonographic
(arrow) against a background of hypoechoic, enlarged thyroid with curvilin
characteristic of Hashimoto’s thyroiditis. The echogenic nodule is a benignspread at the time of surgery (Table 4). Capsular inva-
sion/abutment correlates with extrathyroidal extension
[30–33], a characteristic of more locally advanced dis-
ease and poorer prognosis. Methods for pre-operative
sonographic evaluation of capsular invasion differ. One
study found that capsular abutment, bulging of the thy-
roid contour, and loss of the echogenic thyroid capsule
have excellent predictive value for excluding or detecting
extracapsular extension [33]. Tumor vascularity and
microcalcifications have shown variable correlation with
extrathyroidal extension and nodal spread [30, 32, 34].
Determination of sonographic features associated
with extracapsular or nodal spread at surgery may be
suggestive of aggressive behavior but is not equivalent
to determining features associated with progression in
potentially indolent thyroid cancers isolated to the thy-
roid gland at diagnosis. One study directly examining
this question was published in 2015 by Fukuoka and
colleagues [35]. This group followed 480 papillary
microcarcinomas over a mean of 6.8 years and sought
to determine features that predicted disease progression
as defined by an increase in size ≥3 mm. Interestingly,
sonographic patterns of microcarcinomas changed over
time; nodules that developed coarse or rim calcifica-
tions tended to have less risk of progression of disease,
and those with poor vascularity also had less chance of
progression. Overall risk of progression was best corre-
lated with calcification pattern and vascularity on the
most recent follow-up.
Investigation into the sonographic features predicting
tumor aggressiveness are still in their early stages. Many
existing studies retrospectively examine thyroid cancer
imaged immediately before surgery, and often those
studies were performed merely to localize a nodule for
fine-needle aspiration, rather than with a focused high-
resolution technique designed for precise local staging.
Additional prospective studies are needed to examine
sonographic features that correlate with poor prognosis;images of the right lobe of the thyroid show an echogenic nodule
ear echogenic bands. These features of the background thyroid are
“white knight” nodule, representing a regenerative nodule
Table 3 Sonographic Patterns, Estimated Risk of Malignancy, and Fine-Needle Aspiration Guidance for Thyroid Nodules, reproduced
from 2015 American Thyroid Association guidelines [14]




High suspicion Solid hypoechoic nodule or solid hypoechoic component of a partially
cystic nodule with one or more of the following features: irregular
margins (infiltrative, microlobulated), microcalcifications, taller than wide




Intermediate suspicion Hypoechoic solid nodule with smooth margins without microcalcifications,
ETE, or taller than wide shape
10–20 Recommend FNA
at ≥1 cm
Low suspicion Isoechoic or hyperechoic solid nodule, or partially cystic nodule with
eccentric solid areas, without microcalcification, irregular margin or ETE,
or taller than wide shape.
5–10 Recommend FNA
at ≥1.5 cm
Very low suspicion Spongiform or partially cystic nodules without any of the sonographic
features described in low, intermediate, or high suspicion patterns.
<3 Consider FNA at
≥2 cm
Observation
without FNA is also
a reasonable option
Benign Purely cystic nodules (no solid component) <1 No biopsy
Hahn et al. Cancers of the Head & Neck  (2017) 2:1 Page 5 of 10as further discussed below, this can safely be performed for
microcarcinomas. For larger cancers in which surveillance
would currently be inappropriate, new studies are needed
that correlate postsurgical natural history with preoperative
sonographic analysis, which may provide additional insight
into which sonographic features suggest aggressive malig-
nancy. Moreover, existing studies significantly differ in their
use of descriptive features. The development of a standard-
ized lexicon such as TI-RADS should facilitate larger,
multi-institutional research to tease out which, if any, sono-
graphic features might be most predictive of clinical behav-
ior. Such studies would ultimately inform the future
modification of TI-RADS and guidelines for clinical man-
agement by recommending immediate surgery, surveil-
lance, or no follow-up.Molecular prognostic factors
The current classification of thyroid neoplasms (and
non-neoplastic thyroid lesions) is based on histopath-
ology [36]. While the existing classification is exceed-
ingly useful, it is apparent that additional refinements
are necessary to ultimately arrive at a classification that
clearly separates biologically (or at least clinically) dis-
tinct entities. As it is clear that the great majority of
“carcinomas” are clinically indolent, even the most
basic distinction between “benign” and “malignant”
requires reappraisal.
As in other areas in oncology, thyroid pathology has gen-
erally been focused on the identification of features that
predict aggressiveness, within the accepted “malignant”
categories of papillary and follicular thyroid carcinoma, the
most common histologic types. While uncommon morpho-
logic subtypes of papillary thyroid carcinoma (PTC) have
been associated with poor prognosis, these often correlatewith staging parameters. The alternative approach (identify-
ing features that predict indolence) is less common but
clearly necessary, as in the recent call to rename encapsu-
lated follicular-variant papillary thyroid carcinoma to “en-
capsulated follicular neoplasm with papillary-like nuclear
features” [37], reflecting the fact that, like follicular aden-
omas, this tumor lacks malignant potential.
Classification and nomenclature are likely to undergo
many more changes in the future as our names for
tumors are informed to a greater and greater extent by
genetic data. The relationship between mutations or
gene expression profiles and histologic patterns is very
complex, but a clearer picture is emerging thanks to
efforts like the Cancer Genome Atlas (TCGA) study on
PTC [38]. It appears that like lung adenocarcinoma,
PTC is typified by a number of “driver” mutations that
are mutually exclusive. Conventional-type papillary thy-
roid carcinomas are largely driven by the BRAF V600E
mutation, while follicular variant PTCs show a high fre-
quency of RAS mutations. Follicular neoplasms (both
follicular adenomas and follicular carcinomas), also show
a high frequency of RAS mutations [39], raising the
question of whether follicular variant PTC is a type of
PTC (by virtue of its nuclear features) or a type of fol-
licular carcinoma (by virtue of its molecular underpin-
nings). Protein kinase fusion genes drive a significant
minority of PTC cases, the spectrum of which overlaps
heavily with fusions seen in lung adenocarcinoma. Both
BRAF mutations and kinase fusions represent opportun-
ities for targeted therapy, an active area of inquiry in
advanced disease.
Thus far, clinical molecular testing in thyroid neoplasia
has largely focused on improving the diagnostic yield of
the fine needle aspiration (FNA) biopsy, the current
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are returned with non-definitive diagnoses, according to
the Bethesda System for Reporting Thyroid Cytopathol-
ogy [40], leading to uncertainty and anxiety. Further-
more, the proportion of cases receiving these diagnoses
varies considerably by institution (and correspondingly,
so does the incidence of cancer within this group) [41].
Most of the molecular assays currently in regular use
were intended to reduce this uncertainty, leading to more
appropriate surgical management. Unfortunately, no one of
these tests currently has both high sensitivity and specifi-
city. Afirma® (Veracyte Inc., South San Francisco CA) is a
commercial gene expression classifier intended to “rule
out” cancer after an atypical FNA result. For thyroid nodule
FNAs interpreted as atypical or suspicious, the test had a
published negative predictive value (NPV) of 85-95%, with
the NPV decreasing in categories with a higher prevalence
of cancer (for example “suspicious” versus “atypia of un-
determined significance”) [42].
Mutational profiling is another method being used.
This approach is exemplified by ThyroSeq®, which was
developed at the University of Pittsburgh. This assay
tests for a number of mutations and fusion genes either
known to occur in cancers or only in benign thyroid
neoplasms. The assay has been expanded several times
to keep pace with newly discovered mutation types, but
it is expensive and still has sensitivity and specificity only
in the 90% range [43].
The molecular correlates of indolence versus aggres-
siveness are not well known, and almost all effort in this
area has been expended towards identifying markers of
aggressiveness. Some evidence suggests that the BRAF
V600E mutation is associated with relatively poorer
prognosis, although overall mortality is very low even in
the BRAF V600E-positive group [44]. However, the
TCGA data demonstrate that there is great biologic het-
erogeneity even within BRAF V600E-positive PTC [38].
TERT promoter mutations may also confer a more
aggressive phenotype, and patients with both BRAF
V600E and TERT promoter mutations appear to have a
higher rate of aggressive disease, even after controlling
for other clinicopathologic factors [45]. Although other
alterations (such as TP53 mutations) are associated with
high-risk cancers, such tumors tend to be histologically
poorly-differentiated or high stage. Aside from the weak
association of BRAF V600E with risk, broad molecular
subtypes (in terms of driver mutations or gene expression
profiling) all contain a mixture of risk groups, and clear
molecular categories without the potential for clinically
aggressive disease have not yet emerged.
We are still establishing the playing field when it
comes to the molecular basis of thyroid cancer. As
sequencing technology becomes more and more avail-
able, the true molecular landscape of these neoplasmswill emerge in all its complexity. Additional studies care-
fully correlating histopathologic and molecular features
are necessary, including studies on benign thyroid neo-
plasms, which are currently poorly understood and
doubtless hold important lessons on the nature of their
malignant cousins. Hopefully, such studies will enable
the confident identification of those cases without a sig-
nificant risk of progression, as well those cases that are
especially aggressive.
Surgical management versus active surveillance of
indolent differentiated thyroid cancer
Identification of indolent thyroid cancer will ultimately
inform the decision to pursue surgical management
versus active surveillance. The 2015 ATA guidelines
recommend either a total thyroidectomy or a thyroid
lobectomy (depending on overall thyroid status, patient
age, personal and family history, etc.) for thyroid can-
cers >1 cm and <4 cm without extrathyroidal extension
and lymph node metastases. On the other hand, a total
thyroidectomy is recommended for all patients with
primary tumors >4 cm, extrathyroidal extension, nodal
metastatic disease, or distant metastatic disease [14].
Any patients with lateral or central neck lymph node
metastases are strongly recommended to have thera-
peutic lateral and/or central neck dissections. For iso-
lated thyroid microcarcinoma (<1 cm), if surgery is
performed, then a lobectomy is considered sufficient.
However, recent literature from Japan has suggested that
active surveillance may be sufficient for thyroid microcar-
cinoma without aggressive features, i.e. those that are
most likely to be indolent. Ito et al. observed 1235 patients
with micropapillary carcinoma and reported that over the
course of 10 years of observation, only 8% had tumors that
increased by ≥3 mm and 3.8% had new nodal metastases.
No patients died or developed distant metastases [46].
Another study by Oda et al. demonstrated that of 1179
patients under active surveillance over an 8 year period,
94 (8.0%) underwent surgery and for most of these pa-
tients (54%), the main reason for surgery was that patients
changed their minds and preferred surgery over continued
surveillance [47].
As discussed, there is no reliable set of clinical or patho-
logic features that can distinguish which patients with thy-
roid carcinomas will progress and develop clinically
significant disease. In addition to determining which
patients are the best candidates for active surveillance, fur-
ther research is needed to clarify optimal methods for ac-
tive surveillance, such as the frequency of surveillance
ultrasound exams. Brito et al. suggest that inappropriate
candidates for active surveillance include those with docu-
mented increase in tumor size of ≥3 mm, subcapsular
location adjacent to the recurrent laryngeal nerve, evi-
dence of aggressive features (extrathyroidal extension, new
Hahn et al. Cancers of the Head & Neck  (2017) 2:1 Page 8 of 10nodal metastases, aggressive cytology on FNA), younger
patients, and those who are unlikely to be compliant with
follow-up [48].
The cost-effectiveness of thyroid lobectomy versus active
surveillance is highly patient dependent and the current
data is inconclusive. Venkatesh et al [49] modeled that
active surveillance was cost-effective for patients who asso-
ciated surveillance with a health utility <0.01 below that of
a thyroid lobectomy, while for the majority (79%) of simula-
tions they modeled, a lobectomy was cost-effective relative
to active surveillance due to the disutility associated with
active surveillance. These authors acknowledge that their
model was not designed to perform individual, patient-
specific simulations, and that patients in whom the diagno-
sis of even indolent microcarcinoma is associated with a
modest decrement in quality of life may benefit from sur-
gery as the cost-effective strategy. Nor did this study
address any comparison between total thyroidectomy and
active surveillance, and limitation to thyroid lobectomy was
an admitted oversimplification of the spectrum of variables.
Lang and Wong [50] also conducted Markov modeling and
determined that active surveillance was cost-effective re-
gardless of patient age, complications, or rates of progres-
sion. However, their study did not attempt to address the
quality of life impact of living with a cancer diagnosis, but
focused specifically on the economic costs associated with
treatment versus surveillance of thyroid cancer. Regardless,
active surveillance is not without risks and these include
the need for close follow-up, frequent exams, and the risk
of disease progression and metastasis.
Thus, in order to address these risks, consideration of
active surveillance needs to be a shared and informed
decision-making process between patients and their
clinicians. Active surveillance also requires consistent
high quality ultrasound exams for the monitoring of not
only thyroid nodules, but also potential lymph node me-
tastases. In the United States, thyroid ultrasound exams
are performed by sonographers, radiologists, surgeons,
and endocrinologists and there is significant variability
in the quality of ultrasonography, especially in consist-
ently identifying smaller thyroid nodules and lymph
node metastases. Brauer et al. reported that the interob-
server variation in measurement of thyroid nodules on
ultrasound is about 50% [51]. While the probability of
experienced ultrasonographers identifying the same thy-
roid nodule is 90% for nodules >1.5 cm, only about a
third of nodules <1 cm could be could be identified as
the same structure by multiple ultrasonographers [51].
Conclusions
Current data suggests that the epidemic of thyroid can-
cer in the United States is primarily an epidemic of diag-
nosis rather than disease: while incidence of thyroid
cancers appears to have tripled between 1975 and 2009,there has been no corresponding change in mortality. A
recently published meta-analysis of autopsy studies has
further confirmed that the prevalence of thyroid cancer
has not significantly changed [52]. Some of the determi-
nants of aggressive behavior in thyroid cancer have been
elucidated, but features associated with indolent behav-
ior per se remain unclear. As active surveillance strat-
egies begin to emerge as an alternative to surgery, future
studies are needed to identify those sonographic features
that augur an indolent clinical course. Genetic analysis
may also prove useful as more markers emerge that pre-
dict not just aggressive behavior, but benignity and indo-
lence as well. Even after identification of patients with
tumor characteristics that correlate with excellent prog-
nosis, additional work will be needed to study practical
considerations such as cost or availability of high quality
sonography which may exclude some patients from
active surveillance. Only after addressing all of these
aspects of the workup and management of thyroid can-
cer will a strategy emerge for treating thyroid cancer
effectively while avoiding needlessly aggressive therapy.
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